<DOC>
	<DOCNO>NCT00006864</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill kidney cancer cell . PURPOSE : Phase IV trial study effectiveness interleukin-2 treating patient metastatic kidney cancer .</brief_summary>
	<brief_title>Interleukin-2 Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall response rate , complete partial response rate , duration response patient metastatic renal cell carcinoma treat low-dose interleukin-2 . - Determine overall survival , one-year progression-free survival , two-year progression-free survival patient treat regimen . - Determine incidence adverse event patient . OUTLINE : This multicenter study . Patients receive low-dose interleukin-2 subcutaneously 5 day week 6 week . Courses repeat every 9 week least 2 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year . PROJECTED ACCRUAL : A total 464 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic renal cell carcinoma Clear cell Papillary Sarcomatoid Mixed Measurable evaluable disease Evidence disease follow surgical resection metastases No CNS disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Hemoglobin least 10 g/dL WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Creatinine great 1.8 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ( barrier plus 1 method ) Thyroidstimulating hormone normal No known hypersensitivity allergy component recombinant human interleukin2 No know autoimmune disease ( e.g. , Crohn 's disease ) No concurrent medical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior recombinant human interleukin2 No concurrent interferon alfa Chemotherapy : No concurrent cytoxic chemotherapy Endocrine therapy : No concurrent hormonal therapy ( e.g. , medroxyprogesterone ) estrogen replacement therapy No concurrent prophylactic glucocorticoid ( replacement dose topical use allow ) No concurrent systemic corticosteroid Radiotherapy : At least 4 week since prior radiotherapy No prior radiotherapy index lesion No concurrent radiotherapy Surgery : See Disease Characteristics Prior surgery renal cell carcinoma allow Other : No prior systemic therapy renal cell carcinoma At least 4 week since prior investigational drug No concurrent investigational drug participation another clinical study No concurrent iodinate radiocontrast dye No concurrent drug another indication purport activity treatment neoplasia ( e.g. , thalidomide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
</DOC>